- Report
- April 2025
- 93 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- March 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 131 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- July 2024
- 105 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- July 2021
- 50 Pages
China
From €2366EUR$2,600USD£2,029GBP
- Report
- October 2024
- 101 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- March 2025
- 215 Pages
China
From €3640EUR$4,000USD£3,121GBP
- Report
- March 2025
- 109 Pages
China
From €1638EUR$1,800USD£1,404GBP
Nifedipine is a calcium channel blocker used to treat high blood pressure and angina. It is a commonly prescribed cardiovascular drug, and is available in both immediate-release and extended-release formulations. Nifedipine is also used to treat preterm labor, Raynaud's phenomenon, and hypertrophic cardiomyopathy. It is generally well-tolerated, but can cause side effects such as headache, dizziness, and swelling.
Nifedipine is available in both generic and brand-name formulations. Brand-name formulations include Procardia, Adalat, and Nifediac. Generic formulations are available from a variety of manufacturers.
In the Nifedipine market, some of the major players include Pfizer, Bayer, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more